ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0044 • ACR Convergence 2025

    DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways

    Rufei Lu1, Tayte Stephens2, Carla Guthridge1, Miles Smith1, Joseph Kheir1, Cristina Arriens1, Joan Merrill3, Marci Beel4, Susan Macwana1, Wade DeJager5, Nicholas Domingez1, Teresa Aberle1, Joel Guthridge1 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Science Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4Oklahoma Medical Research Foun, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with distinct clinical and immunopathological features. Epigenetic modifications, particularly DNA methylation, contribute to…
  • Abstract Number: 0018 • ACR Convergence 2025

    Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases

    Lin Huan, Hao Ran, Shiyi Wang, Xiaoping Zhang, Bing Yang, Yang He, Dandan Liu, Chenpeng Su, Chuan Chen, Xiaoqian Chen, Kezhen Ye, Liang Tian, Jian Peng and Zhenping Zhu, Helixon Therapeutics, New York

    Background/Purpose: B cells and autoantibodies play a central role in the pathogenesis of various autoimmune diseases. Although CD19-targeted B cell depletion shows promising therapeutic potential,…
  • Abstract Number: 0357 • ACR Convergence 2025

    Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)

    Jason Xenakis1, Esther Yi1, Iyar Mazar2, Sarah Knight3, Harriet Makin3, Samantha Wratten3, Rohit Aggarwal4 and Stephanie McKee3, 1Pfizer Inc., New York, United States of America, New York, 2Pfizer, US, New York, 3Clarivate, London, United Kingdom, 4University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease…
  • Abstract Number: 0024 • ACR Convergence 2025

    Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease

    Daniel Panyard1, Daniel Li2, Pik Fang Kho2, Rodrigo Guarischi-Sousa3, Jiayan Zhou2, Austin Hilliard4, Christie Bartels5, Philip Tsao2 and Themistocles Assimes2, 1Stanford University, Sunnyvale, CA, 2Stanford University, Palo Alto, CA, 3Palo Alto Veterans Institute for Research, Palo Alto, CA, 4VA Palo Alto Health Care, Palo Alto, CA, 5University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
  • Abstract Number: 0311 • ACR Convergence 2025

    Time series analysis of continuous accelerometry data to determine the impact of symptomatic multiple joint osteoarthritis (MJOA) in the naturally occurring canine model

    Elizabeth Kawecki-Wright1, Liubov Arbeeva2, Christina Stevens1, Masataka Enomoto1, Amanda Nelson3, Margaret Gruen1 and Duncan Lascelles1, 1North Carolina State University, RALEIGH, NC, 2University of North Carolina, Chapel Hill, Carrboro, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Pet dogs are a promising translational model for naturally occurring multiple joint osteoarthritis (MJOA). We characterized the impact of symptomatic (sx) MJOA, over the…
  • Abstract Number: 0297 • ACR Convergence 2025

    Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis

    Natasha Le Blanc1, Marie Hudson1, Ana Cristina Gonzalez Sanchez2, Lina Marcela Diaz Gallo2 and Valerie Leclair3, 1McGill University, Montréal, QC, Canada, 2Karolinska Institutet, Stockholm, Sweden, 3McGill University, Montréal, Canada

    Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
  • Abstract Number: 0319 • ACR Convergence 2025

    Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis

    Danielle Madison1, Adriana Morales Rivera2, Dylon Collins2, Isabel Lam2, Daniel Khokhar2, Garrett Snyder2, Anthony Thompson2, Mark Soliman2, Daniela Carralero Somoza2 and Michael Sabina2, 1Lakeland Regional Medical Center, Lakeland, FL, 2Lakeland Regional Medical Center, Lakeland

    Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
  • Abstract Number: 0344 • ACR Convergence 2025

    Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention

    Gregory Challener1, Zandra E. Walton1, Christine M. Parsons1, Aakash V. Patel2, Alex Tinianow3, Molly E. Griffin1, Raisa Lomanto Silva3, Avira Som1, Laura J. Yockey4, WuQiang Fan5, Sheila L. Arvikar1 and Marcy Bolster6, 1Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Boston, MA, 4MGH, Charlestown, MA, 5Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, 6Massachusetts General Hospital, Concord, MA

    Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
  • Abstract Number: 0226 • ACR Convergence 2025

    Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic

    Justin Levinson1 and Christie Bartels2, 1University of Wisconsin- Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Geriatric integrative care models, such as the Perioperative Optimization of Senior Health (POSH) initiative, have shown improved outcomes (PMID: 29299599), yet there remains limited…
  • Abstract Number: 0233 • ACR Convergence 2025

    Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis

    Godbless Ajenaghughrure1, Sila Mateo Faxas2, Gurjot Singh3, Nirys Mateo Faxas4, Kim Nguyen3, Nicole Tejeda5 and Kimberly Ramirez Bonetti6, 1Trihealth Good Samaritan Hospital, Cincinnati, OH, 2Good Samaritan Hospital, Cincinnati, OH, 3Trihealth Good Samaritan Hospital, Cincinnati, 4Independent Author, Santo Domingo, Dominican Republic, 5Independent Author, Cincinnati, 6Independent Author, cincinnati, OH

    Background/Purpose: While both SGLT2 inhibitors and GLP-1 receptor agonists improve glycemic control in type 2 diabetes (T2D), their safety profiles, particularly regarding hypoglycemia and infection…
  • Abstract Number: 0247 • ACR Convergence 2025

    Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis

    Elizabeth Volkmann1, Steven Nathan2, Karen Coeytaux3, Yanni Fan4, Jill Curran3, Haikun Bao3, Kamila Sroka-Saidi5, Ann Chauffe6 and Jeffrey J Swigris7, 1Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, 2Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 4Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, 5Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 6Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, 7Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver

    Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
  • Abstract Number: 0332 • ACR Convergence 2025

    Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis

    Mohamed Abdelsalam1, Maryam Lasheen2, Hadeer Hafez3, Bassant Elaraby Elsayed Badwy4, Omar Sameh Nabil El Sedafy1 and Mohamed Reda Awad5, 1Misr University For Science and Technology, 6 october, Al Jizah, Egypt, 2Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, 36th October University, 6 october, Al Jizah, Egypt, 4Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, 5Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

    Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
  • Abstract Number: 0340 • ACR Convergence 2025

    Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.

    Chern Lee Choy1, Hamzah Amin2 and marwan Bukhari3, 1University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom

    Background/Purpose: It is well recognized that inflammatory bowel disease (IBD) is associated with osteoporosis and fragility fractures, likely due to multiple factors, including systemic inflammation,…
  • Abstract Number: 0339 • ACR Convergence 2025

    Evaluating Discordance between Bilateral Hip Bone Density Measurements in Individuals with Low Bone Mass

    Anupama Shahane1, Nora Sandorfi2 and Alexis Ogdie1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, USA, Philadelphia

    Background/Purpose: Bone mineral density (BMD) measurement by dual X-ray absorptiometry (DXA) is the basis of World Health Organization (WHO) classification criteria for osteoporosis. Traditionally unilateral…
  • Abstract Number: 0283 • ACR Convergence 2025

    The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records

    Ana Valle1, Amy Vo2, Rochelle Castillo1, Yumeko Kawano3, Leah Santacroce3, Daniel Solomon4, Katherine Liao3 and Candace Feldman3, 1Brigham and Women's Hospital, Brookline, MA, 2Harvard Medical School, Boston, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM; including dermatomyositis, polymyositis, and inclusion body myositis) are heterogenous systemic inflammatory conditions that cause significant disability and morbidity. The study…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology